NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03553836,Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716),https://clinicaltrials.gov/study/NCT03553836,,ACTIVE_NOT_RECRUITING,"This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo.

Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.",YES,Melanoma,BIOLOGICAL: Pembrolizumab|OTHER: Placebo,"Recurrence-free Survival (RFS), RFS was defined as the time from randomization to any of the following events: recurrence of melanoma at any site (local, in-transit or regional lymph nodes or distant recurrence) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. Per protocol, final analysis for this primary outcome measure was performed using the initial pembrolizumab or placebo treatment with a protocol-specified analysis data cut-off date of June-21-2021., Up to ~32.7 months","Distant Metastasis-free Survival (DMFS), DMFS will be defined as the time from randomization to the first diagnosis of a distant metastasis per RECIST 1.1. Distant metastasis will refer to cancer that has spread from the original (primary) tumor and beyond local tissues and lymph nodes to distant organs or distant lymph nodes. DMFS will be reported for randomized participants., Up to ~9 years|Overall Survival (OS), OS will be defined as the time from randomization to death due to any cause. OS will be reported for randomized participants., Up to ~15 years|Number of Participants Who Experienced at Least One Adverse Event (AE), An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, analysis for this outcome measure was performed using the initial pembrolizumab or placebo treatment., Up to ~19.3 months|Number of Participants Who Discontinued Study Treatment Due to an AE, An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Per protocol, analysis for this outcome measure was performed using the initial pembrolizumab or placebo treatment., Up to ~19.3 months",,Merck Sharp & Dohme LLC,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,976,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",3475-716|MK-3475-716|KEYNOTE-716|205203|2022-501966-23|U1111-1282-6109|2018-000669-35,2018-09-12,2021-06-21,2033-10-12,2018-06-12,2022-06-24,2024-11-29,"University of Arizona Cancer Center ( Site 0121), Tucson, Arizona, 85719, United States|UCSD Moores Cancer Center ( Site 0133), La Jolla, California, 92037, United States|The Angeles Clinic and Research Institute ( Site 0029), Los Angeles, California, 90025, United States|UCLA Hematology & Oncology ( Site 0130), Los Angeles, California, 90095, United States|John Wayne Cancer Institute ( Site 0026), Santa Monica, California, 90404, United States|University of Colorado Cancer Center ( Site 0027), Aurora, Colorado, 80045, United States|Yale University ( Site 0035), New Haven, Connecticut, 06511, United States|Mayo Clinic Florida ( Site 0024), Jacksonville, Florida, 32224, United States|Moffitt McKinley Outpatient Center ( Site 0131), Tampa, Florida, 33612, United States|Winship Cancer Institute of Emory University ( Site 0046), Atlanta, Georgia, 30322-1013, United States|Northside Hospital ( Site 0115), Atlanta, Georgia, 30341, United States|Northwestern Medical Group ( Site 0135), Chicago, Illinois, 60611, United States|The University of Chicago Medical Center ( Site 0007), Chicago, Illinois, 60637, United States|Advocate Medical Group-Park Ridge ( Site 0025), Park Ridge, Illinois, 60068, United States|University of Iowa Hospital and Clinics ( Site 0001), Iowa City, Iowa, 52242, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0047), Baltimore, Maryland, 21287, United States|Massachusetts General Hospital ( Site 0126), Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center ( Site 0141), Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute ( Site 0124), Boston, Massachusetts, 02215, United States|Karmanos Cancer Institute ( Site 0111), Detroit, Michigan, 48201, United States|Mayo Clinic [Rochester, MN] ( Site 0016), Rochester, Minnesota, 55905, United States|Siteman Cancer Center ( Site 0143), Saint Louis, Missouri, 63110, United States|Memorial Sloan Kettering ( Site 0006), Harrison, New York, 10604, United States|Laura and Isaac Perlmutter Cancer Center ( Site 0137), New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center ( Site 0142), New York, New York, 10022, United States|Mount Sinai Medical Center ( Site 0038), New York, New York, 10029, United States|University of Rochester ( Site 0019), Rochester, New York, 14642, United States|The Lindner Center for Research and Education at The Christ Hospital ( Site 0004), Cincinnati, Ohio, 45219, United States|Stephenson Cancer Center ( Site 0042), Oklahoma City, Oklahoma, 73104, United States|Oregon Health & Science University ( Site 0032), Portland, Oregon, 97239, United States|Children's Hospital of Pittsburgh UPMC ( Site 0144), Pittsburgh, Pennsylvania, 15224, United States|UPMC Hillman Cancer Centers ( Site 0043), Pittsburgh, Pennsylvania, 15232, United States|West Cancer Center - East Campus ( Site 0022), Germantown, Tennessee, 38138, United States|University of Tennessee Medical Center Knoxville ( Site 0116), Knoxville, Tennessee, 37920, United States|University of Texas-MD Anderson Cancer Center ( Site 0134), Houston, Texas, 77030, United States|Inova Schar Cancer Institute ( Site 0014), Fairfax, Virginia, 22031, United States|VCU Massey Cancer Center ( Site 0008), Richmond, Virginia, 23298, United States|Seattle Cancer Care Alliance ( Site 0044), Seattle, Washington, 98109, United States|University of Wisconsin Hospital and Clinics ( Site 0030), Madison, Wisconsin, 53792, United States|Melanoma Institute Australia ( Site 0856), North Sydney, New South Wales, 2065, Australia|Westmead Hospital ( Site 0853), Westmead, New South Wales, 2145, Australia|Cairns Base Hospital ( Site 0859), Cairns, Queensland, 4870, Australia|Tasman Oncology Research Pty Ltd ( Site 0858), Southport, Queensland, 4215, Australia|Princess Alexandra Hospital ( Site 0857), Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital ( Site 0861), Adelaide, South Australia, 5000, Australia|Ashford Cancer Centre Research ( Site 0860), Kurralta Park, South Australia, 5037, Australia|The Alfred Hospital ( Site 0852), Melbourne, Victoria, 3004, Australia|Fiona Stanley Hospital ( Site 0851), Murdoch, Western Australia, 6150, Australia|GZA Sint Augustinus ( Site 0259), Wilrijk - Antwerpen, Antwerpen, 2610, Belgium|Cliniques Universitaires Saint-Luc ( Site 0251), Brussels, Bruxelles-Capitale, Region De, 1200, Belgium|Institut Jules Bordet ( Site 0254), Bruxelles, Bruxelles-Capitale, Region De, 1000, Belgium|Jessa Ziekenhuis Campus Virga Jesse ( Site 0256), Hasselt, Limburg, 3500, Belgium|UZ Gent ( Site 0255), Gent, Oost-Vlaanderen, 9000, Belgium|UZ Leuven ( Site 0252), Leuven, Vlaams-Brabant, 3000, Belgium|Hospital Erasto Gaertner ( Site 0159), Curitiba, Parana, 81520-060, Brazil|Hospital de Caridade de Ijui ( Site 0156), Ijui, Rio Grande Do Sul, 98700 000, Brazil|Hospital Sao Vicente de Paulo ( Site 0158), Passo Fundo, Rio Grande Do Sul, 99010-080, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0154), Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0155), Barretos, Sao Paulo, 14784-400, Brazil|Hospital de Clinicas de Rio Preto ( Site 0162), Sao Jose Do Rio Preto - SP, Sao Paulo, 15090-000, Brazil|Instituto Nacional do Cancer II ( Site 0160), Rio de Janeiro, 20220-410, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0151), Sao Paulo, 01246-000, Brazil|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0161), Sao Paulo, 01321-001, Brazil|A.C. Camargo Cancer Center ( Site 0164), Sao Paulo, 01508-010, Brazil|Cross Cancer Institute ( Site 0057), Edmonton, Alberta, T6G 1Z2, Canada|CancerCare Manitoba ( Site 0053), Winnipeg, Manitoba, R3E 0V9, Canada|Moncton Hospital - Horizon Health Network ( Site 0055), Moncton, New Brunswick, E1C 6Z8, Canada|The Ottawa Hospital ( Site 0058), Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Research Institute ( Site 0060), Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Cancer Centre ( Site 0059), Toronto, Ontario, M5G 2M9, Canada|Hopital Maisonneuve Rosemont ( Site 0056), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0054), Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre ( Site 0062), Montreal, Quebec, H4A 3J1, Canada|CHU de Quebec - Hotel-Dieu de Quebec ( Site 0061), Quebec, G1R 2J6, Canada|Instituto Clinico Oncologico del Sur ( Site 0203), Temuco, Araucania, 4810469, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0200), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile ( Site 0201), Santiago, Region M. De Santiago, 8330032, Chile|Sociedad Medica Aren y Bachero Limitada ( Site 0207), Santiago, Region M. De Santiago, 8420383, Chile|Oncocentro ( Site 0204), Vina del Mar, Valparaiso, 2520598, Chile|Centro Oncologico Antofagasta ( Site 0206), Antofagasta, 1240000, Chile|Hopital La Timone ( Site 0302), Marseille, Bouches-du-Rhone, 13385, France|CHU Dijon Bourgogne ( Site 0320), Dijon, Cote-d Or, 21000, France|CHU de Bordeaux- Hopital Saint Andre ( Site 0304), Bordeaux, Gironde, 33075, France|Institut Claudius Regaud IUCT Oncopole ( Site 0306), Toulouse, Haute-Garonne, 31059, France|Hopital Ambroise Pare Boulogne ( Site 0316), Boulogne-Billancourt, Hauts-de-Seine, 92100, France|CHU Montpellier. ( Site 0312), Montpellier, Herault, 34295, France|Centre Eugene Marquis ( Site 0305), Rennes, Ille-et-Vilaine, 35042, France|CHU Angers ( Site 0321), Angers, Maine-et-Loire, 49933, France|CHU de Reims ( Site 0307), Reims, Marne, 51100, France|CHRU Lille - Hopital Claude Huriez ( Site 0301), Lille, Nord, 59037, France|C.H.U. Lyon Sud ( Site 0303), Pierre Benite, Rhone, 69495, France|CHU Amiens Picardie Hopital Nord ( Site 0317), Amiens, Somme, 80054, France|Institut Gustave Roussy ( Site 0300), Villejuif, Val-de-Marne, 94805, France|Hopital Saint Louis ( Site 0322), Paris, 75475, France|Universitaetsklinikum in Mannheim ( Site 0351), Mannheim, Baden-Wurttemberg, 68135, Germany|Universitaetsklinikum Tuebingen ( Site 0353), Tuebingen, Baden-Wurttemberg, 72076, Germany|Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 0357), Muenchen, Bayern, 80337, Germany|Klinikum Nuernberg Nord ( Site 0355), Nuernberg, Bayern, 90419, Germany|Klinikum der Universitaet in Wuerzburg ( Site 0356), Wuerzburg, Bayern, 97080, Germany|Elbe Klinikum Buxtehude ( Site 0354), Buxtehude, Niedersachsen, 21614, Germany|Medizinische Hochschule Hannover ( Site 0358), Hannover, Niedersachsen, 30625, Germany|Klinik und Poliklinik fuer Dermatologie Venerologie und Allergologie ( Site 0361), Essen, Nordrhein-Westfalen, 45147, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0359), Kiel, Schleswig-Holstein, 24105, Germany|SRH Wald-Klinikum Gera GmbH ( Site 0360), Gera, Thuringen, 07548, Germany|Universitaetsklinikum Hamburg Eppendorf (UKE) ( Site 0352), Hamburg, 20246, Germany|Soroka Medical Center ( Site 0653), Beer Sheva, Southern, 8457108, Israel|Sourasky Medical Center ( Site 0656), Tel Aviv, Tell Abib, 6423906, Israel|HaEmek Medical Center ( Site 0655), Afula, 1834111, Israel|Rambam Medical Center ( Site 0654), Haifa, 3109601, Israel|Hadassah Ein Kerem Medical Center ( Site 0651), Jerusalem, 9112001, Israel|Chaim Sheba Medical Center. ( Site 0652), Ramat Gan, 5262000, Israel|Shamir Medical Center-Assaf Harofeh ( Site 0657), Zerifin, 70300, Israel|Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 0403), Meldola, Forli-Cesena, 47014, Italy|IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0406), Bari, 70124, Italy|ASST Papa Giovanni XXIII ( Site 0402), Bergamo, 24127, Italy|IRCCS A.O.U. San Martino - IST ( Site 0404), Genova, 16132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0408), Milano, 20133, Italy|Istituto Nazionale Tumori Fondazione Pascale ( Site 0400), Napoli, 80131, Italy|IRCCS Istituto Oncologico Veneto ( Site 0407), Padova, 35128, Italy|IDI - Istituto Dermopatico dell'Immacolata ( Site 0405), Roma, 00167, Italy|Azienda Ospedaliero Universitaria Senese ( Site 0401), Siena, 53100, Italy|National Cancer Center Hospital ( Site 0910), Tokyo, 104-0045, Japan|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 0769), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Pratia MCM Krakow ( Site 0773), Krakow, Malopolskie, 30-510, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0751), Warszawa, Mazowieckie, 02-781, Poland|Instytut Pomnik Centrum Zdrowia Dziecka ( Site 0759), Warszawa, Mazowieckie, 04-730, Poland|Kliniczny Szpital Wojewodzki Nr 1 ( Site 0758), Rzeszow, Podkarpackie, 35-055, Poland|Uniwersyteckie Centrum Kliniczne ( Site 0770), Gdansk, Pomorskie, 80-402, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 0754), Bielsko-Biala, Slaskie, 43-300, Poland|Uniwersyteckie Centrum Kliniczne Slaskiego Uniwersytetu Medycznego ( Site 0757), Katowice, Slaskie, 40-514, Poland|LIFTMED ( Site 0765), Rybnik, Slaskie, 44-200, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 0753), Poznan, Wielkopolskie, 60-780, Poland|Cancer Care Langenhoven Drive Oncology Centre ( Site 0812), Port Elizabeth, Eastern Cape, 6045, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 0801), Johannesburg, Gauteng, 2196, South Africa|Charlotte Maxeke Johannesburg Academic Hospital ( Site 0811), Parktown, Gauteng, 2196, South Africa|Wilgers Oncology Centre ( Site 0806), Pretoria, Gauteng, 0081, South Africa|MPOC ( Site 0803), Pretoria, Gauteng, 0181, South Africa|Cancercare ( Site 0810), Cape Town, Limpopo, 7700, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 0807), Kraaifontein, Western Cape, 7570, South Africa|Onkologikoa - Instituto Oncologico de San Sebastian ( Site 0457), San Sebastian, Gipuzkoa, 20014, Spain|Hospital General Universitario de Valencia ( Site 0451), Valencia, Valenciana, Comunitat, 46014, Spain|Hospital General Universitari Vall d Hebron ( Site 0456), Barcelona, 08035, Spain|Hospital Clinic de Barcelona ( Site 0452), Barcelona, 08036, Spain|Hospital General Universitario Gregorio Maranon ( Site 0454), Madrid, 28009, Spain|Hospital Universitario Virgen Macarena ( Site 0455), Sevilla, 41009, Spain|Universitaetsspital Basel ( Site 0554), Basel, Basel-Stadt, 4031, Switzerland|Universitaetsspital Bern ( Site 0552), Bern, Berne, 3010, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 0556), Geneva, Geneve, 1211, Switzerland|Kantonsspital Graubuenden ( Site 0555), Chur, Grisons, 7000, Switzerland|Kantonsspital St. Gallen ( Site 0559), St. Gallen, Sankt Gallen, 9007, Switzerland|Oncological Institute of Southern Switzerland ( Site 0557), Bellinzona, Ticino, 6500, Switzerland|Centre Hospitalier Universitaire Vaudois ( Site 0553), Lausanne, Vaud, 1011, Switzerland|Hopital du Valais ( Site 0558), Sion, Wallis, 1951, Switzerland|Universitaetsspital Zuerich ( Site 0551), Zuerich, Zurich, 8091, Switzerland|Addenbrooke's Hospital in Cambridge ( Site 0600), Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Guy s & St Thomas NHS Foundation Trust ( Site 0601), London, London, City Of, SE1 9RT, United Kingdom|Royal Marsden Hospital - Fulham Road London ( Site 0613), London, London, City Of, SW3 6JJ, United Kingdom|The Royal Marsden NHS Foundation Trust. ( Site 0612), Sutton, Surrey, SM2 5PT, United Kingdom|Christie NHS Foundation Trust ( Site 0604), Manchester, M20 4GJ, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/36/NCT03553836/SAP_001.pdf"
